Core Insights - Shanghai Xinguang Biomedical Co., Ltd. has completed a Pre-A++ financing round led by Xingfu Capital, marking its third financing in the past 12 months [1] - The funds will primarily be used to accelerate the mass production and registration of its portable dialysis machine [1] - The company aims to innovate in the dialysis field and establish a domestic technological barrier in China [2] Company Overview - Founded in 2018 at Fudan Science Park, the company focuses on making dialysis technology more accessible for over three million uremic patients globally [1] - The company emphasizes the need for disruptive innovation in the dialysis sector, particularly in the context of China's medical device industry [2] Industry Context - As of 2023, the total number of dialysis patients in China has exceeded 1.06 million, with an annual increase of 185,000 patients, reflecting a stable compound annual growth rate of 12% to 14% [1] - The dialysis industry faces challenges from centralized procurement policies that limit profit margins and the development of "Me too" products [2][3] - The company has achieved significant breakthroughs in large animal model experiments, gaining recognition from leading medical experts and investment institutions [3] Future Prospects - The company is working on a home dialysis solution that is cost-effective and improves dialysis adequacy through a dialysis fluid regeneration scheme [3] - Future plans include remote intelligent monitoring of the entire dialysis process and patient vital sign data monitoring, aiming to provide comprehensive treatment and follow-up management for end-stage renal disease patients [3]